| A | B | C | D | E | F | G | H | I | |
|---|---|---|---|---|---|---|---|---|---|
1 | MELANOMA - CLINICAL TRIALS | ||||||||
2 | Source: clinicaltrials.gov (Advanced / Recurrent / Metastatic) | ||||||||
3 | |||||||||
4 | ICAN advises every patient and other interested person, after reviewing this clinical trials spreadsheet, to check out clinical trials directly at www.cancer.gov in case there are updates since the date of this posting. ICAN does not purport to provide medical advice or to indicate which trial is suitable for a certain patient. Please consult your medical oncology team and the principal investigator in charge of the trial in which you are interested for information most relevant to your specific medical situation and decision-making process. | ||||||||
5 | |||||||||
6 | No. | Link | Official Title | Purpose | Citation | Organization/Sponsor | Collaborator | Status | Criteria |
7 | |||||||||
8 | 1 | http://clinicaltrials.gov/ct2/show/NCT00207298 | Phase III Open Label Trial for Use of [18F]-Fluoro-Deoxy-Glucose (18F-FDG) in Positron Emission Tomography Imaging in Oncology | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT00207298 - Retrieved November 2011 | British Columbia Cancer Agency | Currently recruiting | Recurrent | |
9 | 2 | http://clinicaltrials.gov/ct2/show/NCT00817518 | An Open-label, Dose-escalation Study With Extension to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO4987655, a MEK Inhibitor, Administered Orally as Monotherapy in Patients With Advanced Tumors | This study will determine the maximum tolerated dose and the dose-limiting toxicities of RO4987655 in patients with advanced and/or metastatic solid tumors. In the first part of the study, groups of patients will be sequentially enrolled to receive ascending oral doses of RO4987655 daily for 28 days. The starting dose of 1mg daily will be escalated in subsequent groups of patients after a successful assessment of the safety and tolerability of the previous dose. In Part 2 of the study, patients with metastatic or advanced malignant melanoma, or any other responsive tumor type, will be randomized to receive either the maximum tolerated dose or the optimal biological dose of RO4987655 daily. The anticipated time on study treatment is until disease progression, and the target sample size is <100 individuals. | http://clinicaltrials.gov/ct2/show/NCT00817518 - Retrieved November 2011 | Hoffmann-La Roche | Currently recruiting | Advanced / Metastatic | |
10 | 3 | http://clinicaltrials.gov/ct2/show/NCT00758797 | In Situ Photoimmunotherapy: A Tumor Directed Treatment for Advanced Melanoma With Cutaneous Metastases | A novel treatment for metastatic melanoma combining a laser and an immune-system stimulating cream. | http://clinicaltrials.gov/ct2/show/NCT00758797 - Retrieved November 2011 | Northwestern University | Currently recruiting | Advanced / Metastatic | |
11 | 4 | http://clinicaltrials.gov/ct2/show/NCT00730639 | A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of MDX-1106 in Subjects With Selected Advanced or Recurrent Malignancies | The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated | http://clinicaltrials.gov/ct2/show/NCT00730639 - Retrieved November 2011 | Bristol-Myers Squibb | Ono Pharmaceutical Company, Ltd. | Currently recruiting | Advanced / Recurrent / Metastatic |
12 | 5 | http://clinicaltrials.gov/ct2/show/NCT01021059 | A Phase I Study of Intravenous Recombinant Human IL-15(rhIL-15) in Adults With Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01021059 - Retrieved November 2011 | National Cancer Institute | Currently recruiting | Metastatic | |
13 | 6 | http://clinicaltrials.gov/ct2/show/NCT01436656 | A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma | CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of orally daily administered LGX818, a RAF kinase inhibitor. Patients with locally advanced or metastatic melanoma harboring the BRAF V600 mutation (during dose escalation phase and expansion phase) and patients with metastatic colorectal cancer harboring the BRAF V600 mutation (during the expansion phase) will be enrolled. The study consists of a dose escalation part were cohorts of patients will receive escalating oral doses of LGX818, followed by a safety dose expansion part were patients will be treated with oral dose of LGX818 given at the MTD or RP2D. | http://clinicaltrials.gov/ct2/show/NCT01436656 - Retrieved November 2011 | Novartis Pharmaceuticals | Currently recruiting | Advanced / Metastatic | |
14 | 7 | http://clinicaltrials.gov/ct2/show/NCT00121680 | A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma | The purpose of this study is to study the safety of E7080 administered to patients with solid tumors or lymphomas. Please note this study is now recruiting patients with advanced and/or metastatic melanoma only. In the current phase of this study, To determine the MTD and the pharmacokenetic profile of E7080 when given as continuous daily (qd) dosing in combination with temozolomide. | http://clinicaltrials.gov/ct2/show/NCT00121680 - Retrieved November 2011 | Eisai Inc. | Currently recruiting | Advanced / Metastatic | |
15 | 8 | http://clinicaltrials.gov/ct2/show/NCT01067066 | A Phase I/II Open-Label Study TPI 287 in Combination With Temozolomide in Patients With Metastatic Melanoma | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01067066 - Retrieved November 2011 | M.D. Anderson Cancer Center | Archer Biosciences, Inc. | Currently recruiting | Metastatic |
16 | 9 | http://clinicaltrials.gov/ct2/show/NCT00565721 | A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT00565721 - Retrieved November 2011 | GE Healthcare | Currently recruiting | Metastatic | |
17 | 10 | http://clinicaltrials.gov/ct2/show/NCT01152788 | A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma | The purpose of this study is to find out what effects an experimental drug, called interleukin 21 or rIL-21, will have on malignant melanoma and whether these effects look promising compared to dacarbazine. In addition, this study will look at the side effects of rIL-21, and some special blood tests will be done to check the level of rIL-21 in the blood. This study will also look at previously removed melanoma tissue to determine which patients might benefit most from this treatment. This research is being done because currently there is no effective treatment for this type of cancer. | http://clinicaltrials.gov/ct2/show/NCT01152788 - Retrieved November 2011 | NCIC Clinical Trials Group | Currently recruiting | Recurrent / Metastatic | |
18 | 11 | http://clinicaltrials.gov/ct2/show/NCT01320085 | A Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600E or NRAS Mutations | The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations. | http://clinicaltrials.gov/ct2/show/NCT01320085 - Retrieved November 2011 | Novartis Pharmaceuticals | Currently recruiting | Advanced / Metastatic | |
19 | 12 | http://clinicaltrials.gov/ct2/show/NCT01028222 | The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation | The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation. | http://clinicaltrials.gov/ct2/show/NCT01028222 - Retrieved November 2011 | Novartis Pharmaceuticals | Currently recruiting | Advanced / Metastatic | |
20 | 13 | http://clinicaltrials.gov/ct2/show/NCT01164007 | An Open Label Study to Determine the Effect of Avastin in Combination With Dacarbazine on Overall Response Rate in Patients With Unresectable/Metastatic Melanoma | This study will assess the preliminary antitumor activity and safety profile of a combination of Avastin and dacarbazine in patients with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease. Patients will receive Avastin 10mg/kg iv every 2 weeks and dacarbazine 800mg/m2 every 4 weeks. The anticipated time on study treatment is until disease progression. | http://clinicaltrials.gov/ct2/show/NCT01164007 - Retrieved November 2011 | Hoffmann-La Roche | Currently recruiting | Metastatic | |
21 | 14 | http://clinicaltrials.gov/ct2/show/NCT01300533 | A Phase I, Open Label , Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 Given by IV Infusion to Patients With Advanced or Metastatic Cancer | The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01300533 - Retrieved November 2011 | BIND Biosciences | Currently recruiting | Advanced /Metastatic | |
22 | 15 | http://clinicaltrials.gov/ct2/show/NCT01460134 | A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors | This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors. | http://clinicaltrials.gov/ct2/show/NCT01460134 - Retrieved November 2011 | Celldex Therapeutics | Currently recruiting | Metastatic | |
23 | 16 | http://clinicaltrials.gov/ct2/show/NCT00948961 | A Phase I/II, Open-Label, Dose-Escalation Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 | The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein. | http://clinicaltrials.gov/ct2/show/NCT00948961 - Retrieved November 2011 | Celldex Therapeutics | Currently recruiting | Advanced | |
24 | 17 | http://clinicaltrials.gov/ct2/show/NCT01082887 | A Phase I/II Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC) | The main objective of this study is to evaluate the clinical and biologic toxicity of cell therapy by adoptive transfer of TIL in combination with intra-tumoral injections of Ad-INFg. | http://clinicaltrials.gov/ct2/show/NCT01082887 - Retrieved November 2011 | Nantes University Hospital | Currently recruiting | Metastatic | |
25 | 18 | http://clinicaltrials.gov/ct2/show/NCT01191775 | A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors | The purpose of this research study is to evaluate the safety of the investigational drug PNT2258 in patients with advance tumors and see how it acts in the body. | http://clinicaltrials.gov/ct2/show/NCT01191775 - Retrieved November 2011 | Pronai Therapeutics, Inc | Currently recruiting | Advanced | |
26 | 19 | http://clinicaltrials.gov/ct2/show/NCT01271803 | A Phase Ib, Open Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of RO5185426 in Combination With GDC-0973 When Administered in Patients With BRAFV600E-Positive Metastatic Melanoma Who Have Progressed After Treatment With RO5185426 | This open-label, dose-escalation study of RO5185426 in combination with GDC-0973 will evaluate the safety, tolerability and pharmacokinetics in patients with BRAF V600 mutation-positive metastatic melanoma. Patients will be assigned to different cohorts with escalating oral doses of RO5185426 and GDC-0973. The anticipated time on study treatment is until disease progression, unacceptable toxicity or any other discontinuation criterion. | http://clinicaltrials.gov/ct2/show/NCT01271803 - Retrieved November 2011 | Hoffmann-La Roche | Currently recruiting | Metastatic | |
27 | 20 | http://clinicaltrials.gov/ct2/show/NCT01006980 | BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine | This randomized, open-label study will evaluate the efficacy, safety and tolerability of RO5185426 as compared to dacarbazine in previously untreated patients with metastatic melanoma. Patients will be randomized to receive either RO5185426 [RG7204; PLEXXIKON: PLX4032] 960 mg orally twice daily or dacarbazine 1000 mg/m2 intravenously every 3 weeks. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs. Patients in the dacarbazine arm may cross over to RO5185426 treatment. | http://clinicaltrials.gov/ct2/show/NCT01006980 - Retrieved November 2011 | Hoffmann-La Roche | Currently recruiting | Metastatic | |
28 | 21 | http://clinicaltrials.gov/ct2/show/NCT01248936 | A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA | This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options | http://clinicaltrials.gov/ct2/show/NCT01248936 - Retrieved November 2011 | Hoffmann-La Roche | Currently recruiting | Metastatic | |
29 | 22 | http://clinicaltrials.gov/ct2/show/NCT01253564 | An Open-label, Pilot Study of RO5185426 in Previously Treated Metastatic Melanoma Patients With Brain Metastases | This open-label study will assess the safety and efficacy of RO5185426 in previously treated metastatic melanoma patients with brain metastases. Patients will receive RO5185426 at a dose of 960 mg twice daily orally until disease progression or unacceptable toxicity occurs. | http://clinicaltrials.gov/ct2/show/NCT01253564 - Retrieved November 2011 | Hoffmann-La Roche | Currently recruiting | Metastatic | |
30 | 23 | http://clinicaltrials.gov/ct2/show/NCT01143753 | An Open-label, Multiple Ascending Dose (MAD) Study of the Selective BRAF Inhibitor RO5212054 (PLX3603) to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With BRAF V600-mutated Advanced Solid Tumours | This open-label, multi-center study will evaluate the safety, tolerability, pharmacokinetics and efficacy of RO5212054 [PLX3603] in patients with BRAF V600-mutated advanced solid tumours. Cohorts of patients will receive escalating oral doses of RO5212054. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs. | http://clinicaltrials.gov/ct2/show/NCT01143753 - Retrieved November 2011 | Hoffmann-La Roche | Currently recruiting | Advanced | |
31 | 24 | http://clinicaltrials.gov/ct2/show/NCT00849875 | Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Association With Chemotherapy in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma | The purpose of this clinical trial is to find out how successfully, patients with progressive metastatic cutaneous melanoma, are able to develop an immune response to injections with the immunotherapeutic product GSK1572932A when given in combination with dacarbazine and evaluate the safety of this combination. | http://clinicaltrials.gov/ct2/show/NCT00849875 - Retrieved November 2011 | GlaxoSmithKline | Currently recruiting | Metastatic | |
32 | 25 | http://clinicaltrials.gov/ct2/show/NCT01377025 | A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01377025 - Retrieved November 2011 | University Hospital, Essen | Currently recruiting | Metastatic | |
33 | 26 | http://clinicaltrials.gov/ct2/show/NCT01264380 | A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients | This randomized, open-label, two period crossover study will evaluate the effect of food on the pharmacokinetics of a single dose of RO5185426 and the efficacy and safety of continuous administration in patients with BRAF V600E mutation-positive metastatic melanoma. Patients will be randomized to receive in a crossover design single oral doses of RO5185426 with or without food, with a 10-day washout period between doses. Following the crossover periods, patients will receive RO5185426 orally twice daily on a continuous basis until disease progression or unacceptable toxicity occurs. | http://clinicaltrials.gov/ct2/show/NCT01264380 - Retrieved November 2011 | Hoffmann-La Roche | Currently recruiting | Metastatic | |
34 | 27 | http://clinicaltrials.gov/ct2/show/NCT01358331 | A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of SCH 900353 in Subjects With Advanced Solid Tumors (Protocol No. P06203) | This study of the safety, tolerability, and efficacy of SCH 900353 given as single agent oral therapy for participants with advanced solid tumors will be done into two parts. In Part 1a, there will be a dose escalation to find the preliminary maximum tolerated dose (MTD), and in Part 1b, dose confirmation to find out the recommended Phase 2 dose (RPTD) that will be used in Part 2 of the study. In Part 2 of the study, participants with certain types of metastatic melanoma or metastatic colorectal cancer will be treated to see if SCH 900353 is effective as single agent therapy. | http://clinicaltrials.gov/ct2/show/NCT01358331 - Retrieved November 2011 | Schering-Plough | Not yet recruiting | Advanced / Metastatic | |
35 | 28 | http://clinicaltrials.gov/ct2/show/NCT01096199 | A Phase I Study of TS-1, Cisplatin & RAD001 (Everolimus) | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01096199 - Retrieved November 2011 | National University Hospital, Singapore | Not yet recruiting | Metastatic | |
36 | 29 | http://clinicaltrials.gov/ct2/show/NCT01378975 | An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases | This open-label, single-arm, multicenter study will evaluate the efficacy and safety in patients with metastatic melanoma who developed brain metastases. Patients may or may not have received prior treatment for metastatic melanoma with brain metastases (except treatment with BRAF or MEK inhibitors). Patients will receive oral doses of 960 mg vemurafenib twice daily until disease progression, unacceptable toxicity or consent withdrawal. | http://clinicaltrials.gov/ct2/show/NCT01378975 - Retrieved November 2011 | Hoffmann-La Roche | Currently recruiting | Metastatic | |
37 | 30 | http://clinicaltrials.gov/ct2/show/NCT00304525 | A Phase I/II, Open-label, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RAF265 (CHIR-265)Administered Orally to Patients With Locally Advanced or Metastatic Melanoma. | The purpose of this study is to determine the safety profile, pharmacokinetics, pharmacodynamics and maximum tolerated dose of RAF265 in patients with locally advanced and metastatic melanoma. | http://clinicaltrials.gov/ct2/show/NCT00304525 - Retrieved November 2011 | Novartis Pharmaceuticals | Currently recruiting | Advanced / Metastatic | |
38 | 31 | http://clinicaltrials.gov/ct2/show/NCT01395121 | A Phase II Trial of Nilotinib in the Treatment of Patients With c-KIT Mutated Advanced Acral and Mucosal Melanoma | The aim of this study is to see if a drug called nilotinib (Tasigna®) is effective in the treatment of patients with a rare group of acral and mucosal melanomas that have a change (mutation) in a protein called cKIT. Nilotinib interferes with signalling inside cells with this mutation and it is believed that this may lead to shrinkage of tumours. Acral melanomas are found on the palms and soles and mucosal melanomas start inside body cavities rather than on the skin. | http://clinicaltrials.gov/ct2/show/NCT01395121 - Retrieved November 2011 | Institute of Cancer Research, United Kingdom | Royal Marsden NHS Foundation Trust | Currently recruiting | Advanced |
39 | 32 | http://clinicaltrials.gov/ct2/show/NCT01174238 | http://clinicaltrials.gov/ct2/show/NCT01174238 - Retrieved November 2011 | Metastatic | |||||
40 | 33 | http://clinicaltrials.gov/ct2/show/NCT01323517 | A Phase II Trial of The Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity | The purpose of this study is to see the effect of adding a systemic study drug, Ipilimumab, to two standard chemotherapy drugs, Melphalan and Dactinomycin. The study drug Ipilimumab is an antibody to a normal protein found in the body, CTLA-4. This protein normally allows the immune system (the body's natural defense system that helps fight infections) uses to quiet an immune response. The study drug works by blocking this protein and allowing the immune system to become more active. This study will investigate the effects, of combining ILI (using two standard drugs to treat melanoma, Melphalan and Dactinomycin), with the study drug, Ipilimumab on advanced Melanoma cancer. | http://clinicaltrials.gov/ct2/show/NCT01323517 - Retrieved November 2011 | Memorial Sloan-Kettering Cancer Center | Bristol-Myers Squibb | Currently recruiting | Advanced |
41 | 34 | http://clinicaltrials.gov/ct2/show/NCT00553618 | http://clinicaltrials.gov/ct2/show/NCT00553618 - Retrieved November 2011 | Metastatic | |||||
42 | 35 | http://clinicaltrials.gov/ct2/show/NCT01258855 | A Randomized Phase II Study of Sequential Biotherapy With Aflibercept and High Dose IL-2 Versus High Dose IL-2 Alone in Patients With Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study | This randomized phase II clinical trial is studying how well giving aldesleukin with or without aflibercept works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery | http://clinicaltrials.gov/ct2/show/NCT01258855 - Retrieved November 2011 | Beckman Research Institute | National Cancer Institute | Currently recruiting | Recurrent |
43 | 36 | http://clinicaltrials.gov/ct2/show/NCT01307397 | An Open-label, Multicenter Expanded Access Study of RO5185426 in Patients With Metastatic Melanoma | This open-label, multicenter, expanded access study will evaluate the safety and efficacy of RO5185426 in patients with BRAF V600 mutation-positive metastatic melanoma who have failed at least one previous systemic treatment for metastatic melanoma and are without satisfactory treatment options. Eligible patients will receive RO5185426 (960 mg twice daily orally) until disease progression or unacceptable toxicity occurs. | http://clinicaltrials.gov/ct2/show/NCT01307397 - Retrieved November 2011 | Hoffmann-La Roche | Currently recruiting | Metastatic | |
44 | 37 | http://clinicaltrials.gov/ct2/show/NCT01078961 | A Phase I Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma | This research study involves the use of two investigational drugs: sorafenib and bortezomib. Sorafenib is designed to stop the growth of cells caused by changes associated with cancer. Bortezomib is designed to stop cancer cells from getting rid of waste products. This causes the cells to build up toxic levels of waste that leads to cell death. In the laboratory, the combination of sorafenib and bortezomib has been shown to fight cancer cells better than either drug alone. We are looking to determine if the combination of sorafenib and bortezomib is a safe treatment for patients with advanced melanoma. The effectiveness of this combination will also be assessed. | http://clinicaltrials.gov/ct2/show/NCT01078961 - Retrieved November 2011 | Massachusetts General Hospital | Dana-Farber Cancer Institute; Beth Isreal Deaconess Medical Center; Brigham and Women's Hospital; Bayer; Millennium Pharmaceuticals, Inc. | Currently recruiting | Advanced |
45 | 38 | http://clinicaltrials.gov/ct2/show/NCT01386580 | An Open-label Phase I/IIa Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases | The purpose of this trial is to determine the safety, tolerability, and pharmacokinetics (PK) of 2B3-101 (glutathione pegylated liposomal doxorubicin hydrochloride) and to explore whether enhanced brain delivery of doxorubicin can result in safe and more effective treatment of patients with brain metastases. | http://clinicaltrials.gov/ct2/show/NCT01386580 - Retrieved November 2011 | to-BBB technologies B.V. | Currently recruiting | Advanced / Metastatic | |
46 | 39 | http://clinicaltrials.gov/ct2/show/NCT00588263 | Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individual With Cancer | The intent of the proposed study is to describe the prevalence of the most common recurring mutations in BRCA1 and BRCA2, blmAsh , and the A636P MSH2 mutation among Ashkenazi Jewish individuals with a variety of cancer diagnoses. If a substantial proportion of these samples contain such mutations, future patients presenting with these diseases may wish to undergo genetic counseling and, if appropriate, formal genetic testing. The benefit from such a process would pertain mainly to the families of these individuals. | http://clinicaltrials.gov/ct2/show/NCT00588263 - Retrieved November 2011 | Memorial Sloan-Kettering Cancer Center | Currently recruiting | Recurrent | |
47 | 40 | http://clinicaltrials.gov/ct2/show/NCT01376713 | CD20-Immunotargeting in Metastatic Melanoma Patients- A Prospective, Open Label, Sequential Pilot Study | The purpose of this study is to assess the overall disease control rate of Ofatumumab wo/w Dacarbazine in subjects with American Joint Committee on Cancer (AJCC 2009) unresectable stage III or stage IV melanoma. | http://clinicaltrials.gov/ct2/show/NCT01376713 - Retrieved November 2011 | Medical University of Vienna | Currently recruiting | Metastatic | |
48 | 41 | http://clinicaltrials.gov/ct2/show/NCT01438658 | Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01438658 - Retrieved November 2011 | Hadassah Medical Organization | Currently recruiting | Metastatic | |
49 | 42 | http://clinicaltrials.gov/ct2/show/NCT01316692 | A Phase II Correlative Clinical Trial of MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor, in Patients With Unresectable Stage III or Stage IV Melanoma Disease | This phase II trial is studying how well Aurora A kinase inhibitor MLN8237 works in treating patients with unresectable stage III-IV melanoma | http://clinicaltrials.gov/ct2/show/NCT01316692 - Retrieved November 2011 | Vanderbilt-Ingram Cancer Center | National Cancer Institute | Currently recruiting | Recurrent |
50 | 43 | http://clinicaltrials.gov/ct2/show/NCT01302496 | A Two-stage Phase II Study of Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma | The CTLA-4 blocking monoclonal antibody ipilimumab (MDX-010, BMS-734016), has demonstrated anti-tumor activity in a subgroup of patients with Stage III (unresectable) or Stage IV melanoma (measurable per modified WHO criteria), who have received prior treatment with any regimen (non-experimental or experimental), except a CD-137 agonist or a CTLA4 inhibitor or agonist and relapsed, failed to respond (CR or PR) or did not tolerate that regimen (Wolchok, Neyns et al. 2009; O'Day, Maio et al. 2010). Ipilimumab exerts its therapeutic effect presumably by activating T-lymphocytes that infiltrate the tumor mass to destroy the malignant cells by mechanisms of cytotoxic cellular interaction. Autologous TriMix-DC vaccine can induce a T-cell repertoire that recognizes in a HLA-restricted way the melanoma associated antigens MAGE-A3, MAGE-C2, tyrosinase and gp100. Administration of ipilimumab together with TriMix-DC vaccine therapy may be a more effective treatment for patients with advanced melanoma as compared to either modality alone. | http://clinicaltrials.gov/ct2/show/NCT01302496 - Retrieved November 2011 | Universitair Ziekenhuis Brussel | Vrije Universiteit Brussel | Currently recruiting | Advanced |
51 | 44 | http://clinicaltrials.gov/ct2/show/NCT01209299 | Integrated Molecular Signature for the Prediction of Response to Carboplatin/Paclitaxel-Based Chemotherapy in Metastatic Melanoma | This research study is studying biomarkers in predicting response to chemotherapy in patients with advanced or metastatic melanoma previously treated with carboplatin and paclitaxel with or without sorafenib tosylate. | http://clinicaltrials.gov/ct2/show/NCT01209299 - Retrieved November 2011 | Eastern Cooperative Oncology Group | National Cancer Institute | Not yet recruiting | Advanced / Recurrent / Metastatic |
52 | 45 | http://clinicaltrials.gov/ct2/show/NCT01053819 | Can We Miss Pigmented Lesions in Psoriasis Patients? | In psoriasis patients, thick psoriatic plaques can obscure these lesions, and clinicians rely heavily on visual inspection to recognize suspicious or atypical pigmented lesions. However, successful systemic treatment and subsequent clearing of psoriatic plaques may allow clinicians to better evaluate pigmented lesions, thereby increasing the likelihood of early identification and treatment of suspicious lesions such as nonmelanoma skin cancer and malignant melanoma. | http://clinicaltrials.gov/ct2/show/NCT01053819 - Retrieved November 2011 | University of Alabama at Birmingham | Amgen | Currently recruiting | Metastatic |
53 | 46 | http://clinicaltrials.gov/ct2/show/NCT01009515 | Phase II of Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma | The primary objective of this study is to determine the objective response rate of this drug combination of carboplatin, paclitaxel and temozolomide in the treatment of metastatic or recurrent melanoma. | http://clinicaltrials.gov/ct2/show/NCT01009515 - Retrieved November 2011 | New Mexico Cancer Care Alliance | Currently recruiting | Recurrent / Metastatic | |
54 | 47 | http://clinicaltrials.gov/ct2/show/NCT01364051 | Phase I Study of the Combination of the VEGFR Inhibitor, AZD2171, and MEK Inhibitor, AZD6244, in the Treatment of Solid Malignancies | This phase I trial studies the side effects and best dose of cediranib maleate and selumetinib in treating patients with solid malignancies. | http://clinicaltrials.gov/ct2/show/NCT01364051 - Retrieved November 2011 | Mayo Clinic | National Cancer Institute | Currently recruiting | Recurrent |
55 | 48 | http://clinicaltrials.gov/ct2/show/NCT01236573 | Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12 | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01236573 - Retrieved November 2011 | National Cancer Institute | Currently recruiting | Metastatic | |
56 | 49 | http://clinicaltrials.gov/ct2/show/NCT00670748 | Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT00670748 - Retrieved November 2011 | National Cancer Institute | Currently recruiting | Metastatic | |
57 | 50 | http://clinicaltrials.gov/ct2/show/NCT00665470 | Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT00665470 - Retrieved November 2011 | National Cancer Institute | Currently recruiting | Metastatic | |
58 | 51 | http://clinicaltrials.gov/ct2/show/NCT01413191 | Phase II Study of IMC-A12 in Metastatic Uveal Melanoma | This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. | http://clinicaltrials.gov/ct2/show/NCT01413191 - Retrieved November 2011 | M.D. Anderson Cancer Center | National Cancer Institute | Currently recruiting | Recurrent / Metastatic |
59 | 52 | http://clinicaltrials.gov/ct2/show/NCT01055522 | Dose Definition and Activity Evaluation Study of the Tumor-Targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Combination With Dacarbazine in Patients With Metastatic Melanoma | This Phase II clinical study is an open-label, multicenter study of L19IL2 in combination with Dacarbazine in patients with metastatic melanoma. The study is divided in two parts: a phase IIa part, designed to establish the recommended dose (RD) of L19IL2 when administered in combination with a fixed dose of Dacarbazine, as well as to determine the preliminary tolerability profile; the second phase IIb part evaluates the objective response rate (ORR) including a randomized study with a fixed dose of Dacarbazine with or without L19IL2, dosed at the RD determined in phase IIa. | http://clinicaltrials.gov/ct2/show/NCT01055522 - Retrieved November 2011 | Philogen S.p.A. | Eudax S.r.l. | Currently recruiting | Metastatic |
60 | 53 | http://clinicaltrials.gov/ct2/show/NCT01312506 | Procurement of Central Nervous System and Extracranial Tumor Tissues, Cerebrospinal Fluid, and Serum/Plasma From Patients With Metastatic Melanoma to the CNS and Respective Controls for Gene Expression and Proteomic Profiling | 1. Understand how the original melanoma from the skin spreads to the CNS. In order to study this we need to collect (and compare) the original skin melanoma, the CNS melanoma, as well as any other melanoma that has not metastasized to the CNS. 2.Develop a diagnostic blood test that will early identify subjects at high risk for developing CNS metastasis or patients who may already have CNS metastasis but the MRI or the CAT scan cannot yet detect it. Thus, the investigators plan to collect CSF from subjects like you who have melanoma CNS metastases in order to confirm the presence of this biomarker. | http://clinicaltrials.gov/ct2/show/NCT01312506 - Retrieved November 2011 | University of Pittsburgh | Not yet recruiting | Metastatic | |
61 | 54 | http://clinicaltrials.gov/ct2/show/NCT00859326 | A Phase I/II Study of Daily Oral Dosing With Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients With Metastatic and Unresectable Locally-Advanced Malignant Melanoma | The purpose of this study is to determine the safety and efficacy of the treatment with a combination of chemotherapy drug, temozolomide with a drug-blocking blood vessel formation, sunitinib malate in patients with advanced melanoma.. | http://clinicaltrials.gov/ct2/show/NCT00859326 - Retrieved November 2011 | University of California, Los Angeles | Schering-Plough; Pfizer | Currently recruiting | Advanced / Metastatic |
62 | 55 | http://clinicaltrials.gov/ct2/show/NCT00779714 | Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma | This phase III trial is aimed to investigate the efficacy of an individualized, sensitivity-directed combination chemotherapy in comparison to the standard regimen DTIC. | http://clinicaltrials.gov/ct2/show/NCT00779714 - Retrieved November 2011 | University of Wuerzburg | Hiege-Stiftung gegen Hautkrebs medac GmbH; DCS Innovative Diagnostik Systeme | Currently recruiting | Metastatic |
63 | 56 | http://clinicaltrials.gov/ct2/show/NCT01018004 | Prospective Randomized Trial for the Evaluation of a Theoretical Follow-Up Schedule in Cutaneous Melanoma Patients, the MELFO-Study. | This randomized clinical trial is comparing follow-up schedules to see how well they work in patients with newly diagnosed stage IB or stage II melanoma. | http://clinicaltrials.gov/ct2/show/NCT01018004 - Retrieved November 2011 | University Medical Centre Groningen | Currently recruiting | Recurrent | |
64 | 57 | http://clinicaltrials.gov/ct2/show/NCT01416831 | Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma | The purpose of this study is compare the response rates in patients with metastatic melanoma treated with high-dose IL2 to patients treated with high-dose IL2 along with radiation therapy. | http://clinicaltrials.gov/ct2/show/NCT01416831 - Retrieved November 2011 | Providence Health & Services | Prometheus Laboratories | Currently recruiting | Metastatic |
65 | 58 | http://clinicaltrials.gov/ct2/show/NCT01100528 | Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance | This phase II trial is studying how well giving dacarbazine together with recombinant interferon alfa-2b works in treating patients with primary uveal melanoma with genetic imbalance. | http://clinicaltrials.gov/ct2/show/NCT01100528 - Retrieved November 2011 | Case Comprehensive Cancer Center | Currently recruiting | Recurrent | |
66 | 59 | http://clinicaltrials.gov/ct2/show/NCT00792545 | A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors | This phase I trial is studying the side effects and best dose of dasatinib given together with bevacizumab in treating patients with solid tumor that is metastatic or cannot be removed by surgery. | http://clinicaltrials.gov/ct2/show/NCT00792545 - Retrieved November 2011 | National Cancer Institute | Currently recruiting | Advanced / Recurrent / Metastatic | |
67 | 60 | http://clinicaltrials.gov/ct2/show/NCT00683670 | Mature Dendritic Cell Vaccination Against gp100 in Patients With Advanced Melanoma | The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells. | http://clinicaltrials.gov/ct2/show/NCT00683670 - Retrieved November 2011 | Washington University School of Medicine | Currently recruiting | Advanced | |
68 | 61 | http://clinicaltrials.gov/ct2/show/NCT01026324 | A Phase I/II Study of SCH727965 in Patients With Malignant Melanoma | This phase I/II trial is studying the side effects and best dose of dinaciclib and to see how well it works in treating patients with stage III or stage IV malignant melanoma that cannot be removed by surgery. | http://clinicaltrials.gov/ct2/show/NCT01026324 - Retrieved November 2011 | Dana-Farber Cancer Institute | National Cancer Institute | Not yet recruiting | Recurrent |
69 | 62 | http://clinicaltrials.gov/ct2/show/NCT01256359 | A Double Blind Randomised Phase 2 Trial of Docetaxel With or Without AZD6244 in wt BRAF Advanced Melanoma | This is a randomised, double-blind placebo controlled phase 2 trial. Patient will be randomly assigned 1:1 between 2 treatment arms. They will receive either docetaxel 75mg/m2 IV and placebo given bd, or AZD6244 75mg bd daily with docetaxel 75mg/m2 IV. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244/placebo may be continued beyond this, until disease progression. The objective is to assess whether the combination of AZD6244 with docetaxel is worthy of evaluation in a definitive randomised study, with the null hypothesis being that the combination has activity similar to that of docetaxel alone in this population. After consent has been obtained mutational analysis of tumour BRAF will be performed on archival tumour tissue, where this information is not already known, to assess eligibility for the study. If there is no archival tissue a fresh biopsy will be requested from the patient. A blood sample will also be taken for future genetic analysis. Once taking part in the trial patients will need to attend their oncology unit regularly for monitoring and the delivery of treatment. Patients will undergo complete physical examination at screening, on C1D1, C1D8, C1D15, C2D1, C2D8 and day 1 of every subsequent cycle. Blood for haematology, biochemistry and clotting will be taken at each of these visits. A 12 lead ECG will be performed at screening . Disease assessment will be by CT scanning using modified RECIST criteria after 9 and 18 weeks, then every 3 months until disease progression. | http://clinicaltrials.gov/ct2/show/NCT01256359 - Retrieved November 2011 | University of Oxford | Currently recruiting | Advanced | |
70 | 63 | http://clinicaltrials.gov/ct2/show/NCT00827177 | A Phase 1 Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors | This is an open-label, dose-escalation study of ARQ 197 administered orally in combination with sorafenib. | http://clinicaltrials.gov/ct2/show/NCT00827177 - Retrieved November 2011 | ArQule | Currently recruiting | Advanced | |
71 | 64 | http://clinicaltrials.gov/ct2/show/NCT01011530 | A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma | This is an open-label, multicenter, phase 1, dose escalation study that will evaluate the safety profile, establish Maximum Tolerated Dose (MTD), and inform the recommended phase 2 dose of MLN4924 as well as evaluate antitumor activity in patients with metastatic melanoma | http://clinicaltrials.gov/ct2/show/NCT01011530 - Retrieved November 2011 | Millennium Pharmaceuticals, Inc. | Currently recruiting | Metastatic | |
72 | 65 | http://clinicaltrials.gov/ct2/show/NCT01271907 | Phase II Study of Metastatic Melanoma Using a Nonmyeloablative Lymphodepleting Regimen Followed by Melanoma-Reactive T-Cells Sensitized in Vitro With Peptide-Pulsed Drosophila Cells | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01271907 - Retrieved November 2011 | National Cancer Institute | Currently recruiting | Metastatic | |
73 | 66 | http://clinicaltrials.gov/ct2/show/NCT01433991 | An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) | This is a multicenter, open-label, Phase 1b/2 study which will be conducted in two parts: a Phase 1b part comprising a dose escalation and an expansion cohort; and a Phase 2 part which will comprise two cohorts. The purpose of the Phase 1b part is to identify the maximum tolerated dose (MTD) of E7080 and E7050 in combination in subjects with unresectable advanced or metastatic solid tumors. In the subsequent Phase 1b expansion cohort and Phase 2 cohorts, additional subjects with recurrent glioblastoma or unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will be enrolled to confirm the MTD (expansion cohort) and to further explore the clinical activity of E7050 and E7080. | http://clinicaltrials.gov/ct2/show/NCT01433991 - Retrieved November 2011 | Eisai Inc. | Not yet recruiting | Advanced / Metastatic | |
74 | 67 | http://clinicaltrials.gov/ct2/show/NCT01133977 | An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma. | Primary: Phase Ib: To define the safety, tolerability and maximum tolerated dose (MTD) of E7080 administered in combination with dacarbazine. •Phase II: To evaluate the safety and tolerability of E7080 administered in combination with dacarbazine, compared with dacarbazine alone. Secondary: Phase II: to make a preliminary assessment of the efficacy of E7080 administered in combination with dacarbazine, compared with dacarbazine alone. | http://clinicaltrials.gov/ct2/show/NCT01133977 - Retrieved November 2011 | Eisai Inc. | PharmaBio Development Inc. | Currently recruiting | Metastatic |
75 | 68 | http://clinicaltrials.gov/ct2/show/NCT00723710 | Guidelines to the Intron A® Health Management Program II: A Nursing Support Program for Patients With High-Risk Melanoma Receiving High Dose Intron A Therapy | Patients with malignant melanoma who had undergone surgery will receive adjuvant treatment with high-dose Intron A for one year. The objective of this study is to maximize treatment compliance by proactive management of side effects in a day-to-day healthcare setting. | http://clinicaltrials.gov/ct2/show/NCT00723710 - Retrieved November 2011 | Schering-Plough | Currently recruiting | Recurrent | |
76 | 69 | http://clinicaltrials.gov/ct2/show/NCT01168050 | Phase II Multicentric Uncontrolled National Trial Assessing the Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification. | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01168050 - Retrieved November 2011 | Assistance Publique - Hôpitaux de Paris | Currently recruiting | Metastatic | |
77 | 70 | http://clinicaltrials.gov/ct2/show/NCT01335009 | A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects With Metastatic Melanoma | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01335009 - Retrieved November 2011 | Morphotek | Currently recruiting | Metastatic | |
78 | 71 | http://clinicaltrials.gov/ct2/show/NCT01127594 | A Multi-Center Phase I Dose Escalation Trial to Evaluate Safety and Tolerability of Intra-Arterial Temozolomide for Patients With Advanced Extremity Melanoma Using Normothermic Isolated Limb Infusion | The purpose of this study is to determine the safety profile of intra-arterial temozolomide administration during Isolated Limb Infusion (ILI) by defining the dose limiting toxicities associated with this treatment. This study also aims to determine the maximum tolerated dose of intra-arterial administration of temozolomide during ILI that will be used in a phase II trial. | http://clinicaltrials.gov/ct2/show/NCT01127594 - Retrieved November 2011 | Duke University | Schering-Plough; M.D. Anderson Cancer Center | Currently recruiting | Advanced |
79 | 72 | http://clinicaltrials.gov/ct2/show/NCT01213472 | Study of GSK2241658A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma | This study is investigating the safety, immunogenicity and clinical activity of GSK2241658A antigen-specific cancer immunotherapeutic (ASCI) for the treatment of patients with non-operable and progressing metastatic cutaneous melanoma | http://clinicaltrials.gov/ct2/show/NCT01213472 - Retrieved November 2011 | GlaxoSmithKline | Currently recruiting | Metastatic | |
80 | 73 | http://clinicaltrials.gov/ct2/show/NCT01149343? | Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in Patients With Metastatic Melanoma | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01149343? - Retrieved November 2011 | GlaxoSmithKline | Currently recruiting | Metastatic | |
81 | 74 | http://clinicaltrials.gov/ct2/show/NCT00571116 | Evaluation of Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy (Phase 1b) | The purpose of this research study is to find out how well patients respond and how long their responses last when treated with Disulfiram (DSF) and arsenic trioxide, what side effects are caused by DSF and arsenic trioxide, and how often they occur. Twenty one subjects will be selected to take part of this study. Treatment will be administered in cycles of 12 weeks and the number of cycles a subject participates in will vary based on several factors. Subjects will receive pills orally, two times a day, and continuous bolus infusion over 2-4 hours, daily, Monday-Friday for two weeks followed by a two week rest period. Routine laboratory tests (including blood and urine) and x rays will be done during therapy to check the subject's body's response to treatments. | http://clinicaltrials.gov/ct2/show/NCT00571116 - Retrieved November 2011 | University of California, Irvine | Currently recruiting | Metastatic | |
82 | 75 | http://clinicaltrials.gov/ct2/show/NCT00685750 | Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma | This study intends to analyze the expression of specific sets of markers in tumor samples and in serum from patients with Non-Small Cell lung Cancer (NSCLC) or Stage III or IV melanoma. The data obtained in this study will be used to guide future development of immunotherapies for melanoma or NSCLC patients. Moreover, the analyses will contribute to definition of markers potentially predictive of clinical response to specific anticancer therapies. | http://clinicaltrials.gov/ct2/show/NCT00685750 - Retrieved November 2011 | GlaxoSmithKline | Currently recruiting | Metastatic | |
83 | 76 | http://clinicaltrials.gov/ct2/show/NCT01131234 | A Phase 1, Pharmacokinetic and Pharmacodynamic Study of the Combination of RO4929097 and Cediranib in Patients With Advanced Solid Tumors | This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors. | http://clinicaltrials.gov/ct2/show/NCT01131234 - Retrieved November 2011 | Princess Margaret Hospital, Canada | National Cancer Institute | Currently recruiting | Advanced / Recurrent |
84 | 77 | http://clinicaltrials.gov/ct2/show/NCT01200342 | Phase II Study of Genasense-Carboplatin-Paclitaxel-Combination in Uveal Melanoma | The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied. | http://clinicaltrials.gov/ct2/show/NCT01200342 - Retrieved November 2011 | M.D. Anderson Cancer Center | Genta Incorporated | Currently recruiting | Metastatic |
85 | 78 | http://clinicaltrials.gov/ct2/show/NCT01363206 | GM-CSF and Ipilimumab as Therapy in Metastatic Melanoma, a Phase II Study | The study is an open-label, single arm single Center Phase II study to evaluate the safety and efficacy of the combination of Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF, Leukine) and Ipilimumab (Yervoy) as therapy for patients with unresectable metastatic malignant melanoma. | http://clinicaltrials.gov/ct2/show/NCT01363206 - Retrieved November 2011 | Northern California Melanoma Center | University of California, San Francisco | Currently recruiting | Metastatic |
86 | 79 | http://clinicaltrials.gov/ct2/show/NCT00833807 | Phase I Study Of Hepatic Arterial Infusion Of Nab-Paclitaxel (Abraxane®) In Patients With Metastatic Melanoma In The Liver | The goal of this clinical research is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given directly to the area where the cancer is located. The safety of this drug will also be studied. | http://clinicaltrials.gov/ct2/show/NCT00833807 - Retrieved November 2011 | M.D. Anderson Cancer Center | Currently recruiting | Metastatic | |
87 | 80 | http://clinicaltrials.gov/ct2/show/NCT01124734 | Phase II Trial of High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Metastatic Malignant Melanoma | The investigators have recently observed that many patients who had received high dose Interleukin-2 (IL2) and failed to respond to it but who then go immediately to temozolomide seemed to enjoy extremely good responses which seem better quality and longer duration than typically observed for temozolomide alone. To date, the investigators have observed 5 sequentially treated patients with metastatic melanoma who had failed high dose IL-2 but who then went on to receive immediate temozolomide. Two of these patients had complete responses and 3 had very strong partial response. In a recent phase II study of extended low dose temozolomide alone given in the same manner as the post IL-2 patients noted above, the response rate was 12.5% and all of these were partial responses only. The responses that the investigators observed were at a much higher rate of response as well as much better quality than expected for temozolomide. The responses were also better than those observed when temozolomide was given first and then followed by high dose IL-2. The investigators concluded that perhaps the major benefit the investigators observed was a result of the prior high dose IL-2 therapy modulated by the temozolomide and that the sequence of treatment was clearly crucial for this response. | http://clinicaltrials.gov/ct2/show/NCT01124734 - Retrieved November 2011 | Penn State University | Currently recruiting | Metastatic | |
88 | 81 | http://clinicaltrials.gov/ct2/show/NCT01266603 | A Phase II Trial of High Dose Interleukin-2 (HDIL-2) With Recombinant MAGE-A3 Protein Combined With Adjuvant System AS15 (recMAGE-A3 + AS15) in Patients With Unresectable or Metastatic Melanoma | The goal of this clinical research study is to learn if high-dose interleukin-2 (HDIL-2), when given in combination with recMAGE-A3 + AS15 (Antigen-Specific Cancer Immunotherapeutic, ASCI), can help to control unresectable or metastatic melanoma in patients expressing MAGE-A3 antigen in tumor cells. The safety of this drug combination will also be studied. | http://clinicaltrials.gov/ct2/show/NCT01266603 - Retrieved November 2011 | M.D. Anderson Cancer Center | GlaxoSmithKline | Currently recruiting | Metastatic |
89 | 82 | http://clinicaltrials.gov/ct2/show/NCT00931931 | A Phase I Dose Escalation Study of Intratumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT00931931 - Retrieved November 2011 | Children's Hospital Medical Center, Cincinnati | FDA Office of Orphan Products Development | Currently recruiting | Recurrent |
90 | 83 | http://clinicaltrials.gov/ct2/show/NCT00872391 | Safety and Efficacy of Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Malignant Melanoma of the Uvea | The purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for the planning target volume (PTV) in patients with uveal melanoma. Patients will be followed-up for 10 years after radiotherapy regarding local tumor control, visual acuity, secondary complications and survival. | http://clinicaltrials.gov/ct2/show/NCT00872391 - Retrieved November 2011 | Medical University of Vienna | Currently recruiting | Metastatic | |
91 | 84 | http://clinicaltrials.gov/ct2/show/NCT00450593 | Studies of Familial Melanoma | This clinical trial is studying gene mutations in patients with melanoma and in families with a history of hereditary melanoma. | http://clinicaltrials.gov/ct2/show/NCT00450593 - Retrieved November 2011 | Leeds Cancer Centre at St. James's University Hospital | Currently recruiting | Recurrent | |
92 | 85 | http://clinicaltrials.gov/ct2/show/NCT00739609 | A Phase I Study of 1-methyl-D-tryptophan (D-1MT) in Patients With Relapsed or Refractory Solid Tumors | This study provides an early evaluation of an entirely new class of small molecule agents directed at disruption or elimination of tumor tolerance, a phenomenon now demonstrated to be involved in the growth of many solid tumors. | http://clinicaltrials.gov/ct2/show/NCT00739609 - Retrieved November 2011 | NewLink Genetics Corporation | Currently recruiting | Recurrent | |
93 | 86 | http://clinicaltrials.gov/ct2/show/NCT01234974 | Phase II Study of the IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus in Patients With Relapsed/Refractory Multiple Myeloma | Observe the safety/tolerability and effectiveness in terms of response rate and duration of response of the combination pasireotide + everolimus in the treatment of patients with relapsed/refractory multiple melanoma. | http://clinicaltrials.gov/ct2/show/NCT01234974 - Retrieved November 2011 | Penn State University | Not yet recruiting | Metastatic | |
94 | 87 | http://clinicaltrials.gov/ct2/show/NCT01288963 | The High-Dose Aldesleukin (IL-2) "SELECT" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma | The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after treatment. | http://clinicaltrials.gov/ct2/show/NCT01288963 - Retrieved November 2011 | Dana-Farber Cancer Institute | Currently recruiting | Advanced | |
95 | 88 | http://clinicaltrials.gov/ct2/show/NCT01209676 | A Phase 0, Exploratory Study of the Pharmacodynamics of a Single Intratumoral Dose of IMCgp100, a Monoclonal Receptor Anti-CD3 scFv Fusion Protein, in Subjects With Advanced Unresectable Melanoma | A phase 0, exploratory study of the pharmacodynamics of a single intratumoral dose of IMCgp100, a monoclonal T cell receptor anti-CD3 scFv fusion protein, in subjects with advanced unresectable melanoma to assess the safety and pharmacodynamic properties of single intratumoral doses of IMCgp100 in the setting of advanced unresectable melanoma. Six patients will be enrolled to complete the study over approximately 12-15 months. | http://clinicaltrials.gov/ct2/show/NCT01209676 - Retrieved November 2011 | Abramson Cancer Center of the University of Pennsylvania | Currently recruiting | Advanced | |
96 | 89 | http://clinicaltrials.gov/ct2/show/NCT00179764 | Immunoablative Protocol for Allogeneic Related and Unrelated Hematopoietic Peripheral Blood Stem Cell Transplant (HPBSC) | The purpose of this research study is to evaluate the effectiveness of transplantation of high doses of peripheral blood stem cells (stem cells are special cells found in the blood and bone marrow that produce new blood cells) after treatment with non-myeloablative chemotherapy (not toxic to the bone marrow). In addition, this study will assess the side effects of the transplant. | http://clinicaltrials.gov/ct2/show/NCT00179764 - Retrieved November 2011 | Children's Memorial Hospital | Currently recruiting | Recurrent | |
97 | 90 | http://clinicaltrials.gov/ct2/show/NCT00972933 | Neoadjuvant Anti-CTLA4 Blockade With Ipilimumab in Patients With AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis | Ipilimumab is a manufactured monoclonal antibody, much like the antibodies usually made by the human body to fight off infection; however it is not known why the human body does not "fight off" a cancerous tumor. The idea behind developing this experimental drug is to stimulate the immune system to make antibodies to kill cancer cells. This research study is considered "experimental" because it has not received approval from the Food and Drug Administration (FDA) for the treatment of this type of cancer. This monoclonal antibody has been specifically made to block Cytotoxic T Lymphocyte Antigen 4 (CTLA4), which is a protein found on cells of the immune system. CTLA4 seems to slow down the immune response, so blocking it with an anti-CTLA4 antibody may make the immune response more active. The purpose of this study is to see if Ipilimumab affects the response of the patient's immune system toward their cancer. | http://clinicaltrials.gov/ct2/show/NCT00972933 - Retrieved November 2011 | University of Pittsburgh | Bristol-Myers Squibb | Currently recruiting | Metastatic |
98 | 91 | http://clinicaltrials.gov/ct2/show/NCT00672542 | Phase I Study of Active Immunotherapy of Metastatic Melanoma With Mature Autologous Dendritic Cells Transfected With Tumor Antigen RNA and Small Inhibitory RNAs to Alter Proteasomal Antigen Processing | Transfection with siRNA targeting the immunoproteasome alters proteasome-mediated antigen processing by the dendritic cell, generating TAA-derived peptides that we hypothesize, based on preclinical results, will induce enhanced anti-melanoma immune responses. This phase I study, open to subjects with metastatic melanoma, will assess the safety of vaccination with melanoma tumor associated antigen-encoding RNA-transfected mature dendritic cells derived from monocytes that have been either untreated, transfected with control siRNA, or transfected with siRNA targeting the inducible immunoproteasome beta subunits LMP2, LMP7, and MECL1. A combination of RNAs encoding melanoma tumor associated antigens MART-1, tyrosinase, gp100, and MAGE-3 will be utilized for dendritic cell transfection. The vaccine will be administered by intradermal injection in the extremities. Clinical and laboratory toxicities will be characterized for each study arm. As a secondary objective, this phase I study will also assess the anti-melanoma immune responses, as well as clinical responses, induced by vaccination with this dendritic cell-based product. | http://clinicaltrials.gov/ct2/show/NCT00672542 - Retrieved November 2011 | Duke University | Currently recruiting | Metastatic | |
99 | 92 | http://clinicaltrials.gov/ct2/show/NCT01328535 | Individualized (Timed) Temozolomide Administration as a Means of Immune Reconstitution in Patients With Metastatic Melanoma | This clinical trial studies individualized temozolomide (TMZ) in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as TMZ, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving TMZ at different times, which are determined individually for each patient based on the phase (biorhythm) of the immune system response against the tumor may allow for a better drug response and may kill more tumor cells | http://clinicaltrials.gov/ct2/show/NCT01328535 - Retrieved November 2011 | Mayo Clinic | National Cancer Institute | Currently recruiting | Recurrent / Metastatic |
100 | 93 | http://clinicaltrials.gov/ct2/show/NCT01253096 | A Phase II Study of Intratumoral Application of L19IL2 in Patients With Stage III/IV Melanoma. | This phase II study is designed to test the efficacy and safety of intratumorally administered L19IL2 in patients suffering from metastatic melanoma. It is well documented that the intratumoral administration of IL-2 leads to a high response rate and unexpectedly favorable longtime outcome. | http://clinicaltrials.gov/ct2/show/NCT01253096 - Retrieved November 2011 | Philogen S.p.A | Currently recruiting | Metastatic | |